Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ).
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced a change in the composition of its Nomination Committee, effective March 31, 2025. Mr. Li Li, the chairman of the board, has stepped down from the committee, while Ms. Li Tan, an executive director and deputy general manager, has been appointed as a new member. This change may impact the company’s governance structure and strategic decision-making processes.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of heparin products and other pharmaceutical services. The company is based in the People’s Republic of China and is publicly traded on the Hong Kong Stock Exchange.
YTD Price Performance: 15.66%
Average Trading Volume: 3,120,635
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.43B
See more insights into 9989 stock on TipRanks’ Stock Analysis page.